New Drug Approvals Archive

New Drug Approvals: July 2009

July 1
Multaq (dronedarone) Tablets

Date of Approval: July 1, 2009

Company: Sanofi-aventis

Treatment for: Atrial Fibrillation, Atrial Flutter

Multaq (dronedarone) is antiarrhythmic drug indicated to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter.

FDA Approves Multaq for Patients with Atrial Fibrillation or Atrial Flutter
 
July 7
Alimta (pemetrexed)

New Indication Approved: July 2, 2009

Lilly Receives Fourth FDA Approval for Alimta (pemetrexed for injection) as Maintenance Therapy For Nonsquamous Non-Small Cell Lung Cancer
 
July 10
Effient (prasugrel) Tablets

Date of Approval: July 10, 2009

Company: Daiichi Sankyo Company, Limited and Eli Lilly and Company

Treatment for: Acute Coronary Syndrome

Effient (prasugrel) is an oral antiplatelet agent for the treatment of patients with acute coronary syndrome (ACS) who are managed with percutaneous coronary intervention including coronary stenting.

Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient
 
July 10
Plan B One-Step (levonorgestrel) Tablet

Date of Approval: July 10, 2009

Company: Teva Pharmaceuticals, Inc.

Treatment for: Emergency Contraception

Plan B One-Step (levonorgestrel) is a single dose emergency contraceptive pill to help prevent an unintended pregnancy after unprotected sex or contraceptive failure. Plan B One-Step will be available over-the-counter (OTC) for consumers age 17 or older; women younger than age 17 will require a prescription.

FDA Approves Plan B One-Step, a New One-Pill Emergency Contraceptive
 
July 15
Sumavel DosePro (sumatriptan) Injection

Date of Approval: July 15, 2009

Company: Zogenix, Inc.

Treatment for: Migraine, Cluster Headache

Sumavel DosePro (sumatriptan injection) is a needle-free delivery system to treat acute migraine, with or without aura, and cluster headache.

Sumavel DosePro (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System
 
July 16
Onsolis (fentanyl) Buccal Soluble Film - formerly BEMA Fentanyl

Date of Approval: July 16, 2009

Company: BioDelivery Sciences International, Inc.

Treatment for: Pain

Onsolis consists of a dissolvable polymer film formulated with the opioid narcotic fentanyl for application to the buccal mucosa (inner lining of the cheek). Onsolis is used for the management of breakthrough pain in patients with cancer.

BioDelivery Sciences and Meda Announce FDA Approval of Onsolis
 
July 20
NovoLog (insulin aspart)

Expiration Date Change Approved: July 14, 2009

FDA Approves NovoLog Labeling Update
 
July 21
Tekturna HCT (aliskiren and hydrochlorothiazide)

New Indication Approved: July 16, 2009

FDA Approves Tekturna HCT as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
 
July 22
Acuvail (ketorolac tromethamine) Ophthalmic Solution

Date of Approval: July 22, 2009

Company: Allergan, Inc.

Treatment for: Postoperative Ocular Inflammation

Acuvail (ketorolac tromethamine) is a preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammation following cataract surgery.

Allergan Receives FDA Approval for Acuvail Ophthalmic Solution for the Treatment of Pain and Inflammation Following Cataract Surgery
 
July 23
Forteo (teriparatide (rDNA origin))

New Indication Approved: July 22, 2009

FDA Approves Expanded Use of Lilly's Forteo [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis
 
July 29
Sculptra (injectable poly-L-lactic acid)

New Formulation Approved: July 29, 2009

Treatment for: Facial Lipoatrophy; Facial Wrinkles

FDA Approves Sculptra Aesthetic, a Facial Injectable for Correction of Nasolabial Folds and Other Facial Wrinkles
 
July 30
Tyvaso (treprostinil) Inhalation Solution

Date of Approval: July 30, 2009

Company: United Therapeutics Corporation

Treatment for: Pulmonary Hypertension

Tyvaso (treprostinil) is an inhaled prostanoid analogue indicated for the treatment of pulmonary arterial hypertension.

FDA Approves Tyvaso (treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
 
July 29
Colcrys (colchicine) Tablets

Date of Approval: July 29, 2009

Company: Mutual Pharmaceutical Company, Inc.

Treatment for: Gout, Familial Mediterranean Fever, Gout -- Prophylaxis, Acute Gout

Colcrys (colchicine) is compound derived from the dried seeds of the autumn crocus or meadow saffron (Colchicum autumnale). Colcrys is approved for the prophylaxis and treatment of acute gout flares, and for the treatment of patients with familial Mediterranean fever.

FDA Approves Colcrys (colchicine) for Acute Gout, Mediterranean Fever
 
July 31
Onglyza (saxagliptin) Tablets

Date of Approval: July 31, 2009

Company: Bristol-Myers Squibb Company and AstraZeneca

Treatment for: Diabetes Mellitus Type II

Onglyza (saxagliptin) is a dipeptidyl peptidase-4 (DPP4) inhibitor indicated for the treatment of type 2 diabetes mellitus in adults.

FDA Approves Onglyza (saxagliptin) for Type 2 Diabetes
 
July 31
Lipsovir (acyclovir and hydrocortisone) Topical Cream

Date of Approval: July 31, 2009

Company: Medivir

Treatment for: Herpes Simplex Labialis

Lipsovir is topical combination of hydrocortisone (an anti-inflammatory agent) and acyclovir (an antiviral agent) for the prevention and treatment of cold sores.

The US FDA approves Lipsovir for marketing and sales in US
 
October 22
Colcrys (colchicine)

New Indication Approved: October 16, 2009

FDA Approves Colcrys (colchicine, USP) for Prevention of Gout Flares
 

New Drug Approvals Archive

2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Feb | Jul | Aug | Oct | Nov | Dec

MedNotes
Advertisement

(web3)